TFOS DEWS III was published in 2025, providing clarity on the definition and diagnosis of dry eye disease. The drivers of dry eye were expanded, from just aqueous deficiency and evaporative subtypes, to deficiencies in the different layers of the tear film, lid margin anomalies such as partial blinking, anterior blepharitis and meibomian gland dysfunction, and ocular surface abnormalities in the form of anatomical misalignment, neural dysfunction, ocular surface damage and inflammation, to inform personalised treatment. The role of new technologies will be discussed including the ImmunDX to assess inflammation levels and to aid in the differential diagnosis, along with QMR technology for the treatment of dry eye disease and its emerging regenerative properties.